Li Xinyi, Fu Zhihui, Xu Huajun, Zou Jianyin, Zhu Huaming, Li Zhiqiang, Su Kaiming, Huai De, Yi Hongliang, Guan Jian, Yin Shankai
Department of Otorhinolaryngology-Head and Neck Surgery, Center of Sleep Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yishan Road, Shanghai, 200233 People's Republic of China.
Otolaryngological Institute of Shanghai Jiao Tong University, Yishan Road 600, Shanghai, 200233 People's Republic of China.
Nutr Metab (Lond). 2020 Sep 29;17:83. doi: 10.1186/s12986-020-00501-8. eCollection 2020.
The relationships between apolipoprotein A-I (APOA-I), apolipoprotein B (APOB) with insulin resistance, metabolic syndrome (MetS) are unclear in OSA. We aimed to evaluate whether the multiple single nucleotide polymorphism (SNP) variants of APOA-I and APOB exert a collaborative effect on insulin resistance and MetS in OSA.
Initially, 12 APOA-I SNPs and 30 APOB SNPs in 5259 subjects were examined. After strict screening, four APOA-I SNPs and five APOB SNPs in 4007 participants were included. For each participant, the genetic risk score (GRS) was calculated based on the cumulative effect of multiple genetic variants of APOA-I and APOB. Logistic regression analyses were used to evaluate the relationships between APOA-I/APOB genetic polymorphisms, insulin resistance, and MetS in OSA.
Serum APOB levels increased the risk of insulin resistance and MetS adjusting for age, gender and BMI [odds ratio (OR = 3.168, < 0.001; OR = 6.098, < 0.001, respectively]. APOA-I GRS decreased the risk of insulin resistance and MetS after adjustments (OR = 0.917, = 0.001; OR = 0.870, < 0.001, respectively). APOB GRS had no association with insulin resistance (OR = 1.364, = 0.610), and had weak association with MetS after adjustments (OR = 1.072, = 0.042). In addition, individuals in the top quintile of the APOA-I genetic score distribution had a lower risk of insulin resistance and MetS after adjustments (OR = 0.761, = 0.007; OR = 0.637, < 0.001, respectively).
In patients with OSA, cumulative effects of APOA-I genetic variations decreased the risk of insulin resistance and MetS, whereas multiple APOB genetic variations had no associations with insulin resistance and weak association with MetS.
阻塞性睡眠呼吸暂停（OSA）患者中，载脂蛋白A-I（APOA-I）、载脂蛋白B（APOB）与胰岛素抵抗、代谢综合征（MetS）之间的关系尚不清楚。我们旨在评估APOA-I和APOB的多个单核苷酸多态性（SNP）变体是否对OSA患者的胰岛素抵抗和MetS产生协同作用。
最初，对5259名受试者中的12个APOA-I SNP和30个APOB SNP进行了检测。经过严格筛选，纳入了4007名参与者中的4个APOA-I SNP和5个APOB SNP。对于每位参与者，根据APOA-I和APOB的多个基因变体的累积效应计算遗传风险评分（GRS）。采用逻辑回归分析评估OSA患者中APOA-I/APOB基因多态性、胰岛素抵抗和MetS之间的关系。
校正年龄、性别和体重指数后，血清APOB水平增加了胰岛素抵抗和MetS的风险[比值比（OR）分别为3.168，<0.001；OR为6.098，<0.001]。校正后，APOA-I GRS降低了胰岛素抵抗和MetS的风险（OR分别为0.917，=0.001；OR为0.870，<0.001）。APOB GRS与胰岛素抵抗无关联（OR=1.364，=0.610），校正后与MetS有弱关联（OR=1.072，=0.042）。此外，在APOA-I基因评分分布最高五分位数的个体中，校正后胰岛素抵抗和MetS的风险较低（OR分别为0.761，=0.007；OR为0.637，<0.001）。
在OSA患者中，APOA-I基因变异的累积效应降低了胰岛素抵抗和MetS的风险，而多个APOB基因变异与胰岛素抵抗无关联，与MetS有弱关联。
